Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

2.740 +0.130 (+4.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces 1-for-40 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.